Compare · INM vs TLRY
INM vs TLRY
Side-by-side comparison of InMed Pharmaceuticals Inc. (INM) and Tilray Brands Inc. (TLRY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. INM focuses on Biotechnology: Pharmaceutical Preparations, while TLRY focuses on Medicinal Chemicals and Botanical Products.
- TLRY is the larger of the two at $347.3M, about 40.6x INM ($8.5M).
- INM has been more active in the news (12 items in the past 4 weeks vs 5 for TLRY).
- TLRY has more recent analyst coverage (14 ratings vs 1 for INM).
- Company
- InMed Pharmaceuticals Inc.
- Tilray Brands Inc.
- Price
- -
- -
- Market cap
- $8.5M
- $347.3M
- 1M return
- -
- -25.37%
- 1Y return
- -
- -77.79%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 12
- 5
- Recent ratings
- 1
- 14
InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Tilray Brands Inc.
Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Aphria Inc. Tilray, Inc. was incorporated in 2018 and is based in New York, New York.
Latest INM
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status
- Large owner Adar1 Capital Management, Llc bought $34,572 worth of shares (2,640 units at $13.10) (SEC Form 4)
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by InMed Pharmaceuticals Inc.
- SEC Form 425 filed by InMed Pharmaceuticals Inc.
- SEC Form 424B3 filed by InMed Pharmaceuticals Inc.
Latest TLRY
- 10 Barrel Brewing, Widmer Brothers and Hop Valley Named Official Craft Beer Partners of the Portland Trail Blazers
- Whiskey You Won't Find on Shelves: Breckenridge Distillery Launches the 2 Mile High Whiskey Club
- Tilray Brands Announces Strategy to Strengthen Canadian Cannabis Operations and Drive Profitable Growth
- Breckenridge Distillery and University of Denver Athletics Release Limited-Edition Whiskey Celebrating Record 11th NCAA Men’s Hockey Championship
- Tilray Brands Announces Next Phase of Beverage Transformation
- Blue Point Brewing Co.’s Legendary Cask Ales Festival Returns to Patchogue with 100+ Limited-Release Brews
- West Ham United F.C. and BrewDog Unveil Boleyn Brew: A Fan-Created Matchday Beer Made by Hammers, for Hammers
- SweetWater Brewing Gives Fans the Chance to Win Tickets to Their Dream Show at AEG Venues Across Georgia
- Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets
- SEC Form 10-Q filed by Tilray Brands Inc.